Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: Adults with diabetes inadequately controlled (HbA1c 7–10%) with metformin were randomized to lixisenatide 20 μg once daily (n = 318) or exenatide 10 μg twice daily (n = 316) in a 24-week (main period), open-label, parallel-group, multicenter study. The primary objective was a noninferiority assessment of lixisenatide versus exenatide in HbA1c change from baseline to week 24. RESULTS: Lixisenatide once daily demonstrated noninferiority in HbA1c reduction versus exenatide twice daily. The least squares mean change was −0.79% (mean decrease 7.97 to 7.17%) for lixisenatide versus −0.96% (mean decrease 7.96 to 7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033–0.297), meeting a predefined noninferiority upper CI margin of 0.4%. Responder rate (HbA1c <7.0%) and improvements in fasting plasma glucose were comparable. Both agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with lixisenatide and exenatide, respectively). Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively). Discontinuations attributable to AEs occurred in 33 lixisenatide (10.4%) and 41 exenatide (13.0%) patients. In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P < 0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P < 0.05). CONCLUSIONS: Add-on lixisenatide once daily in type 2 diabetes inadequately controlled with metformin demonstrated noninferior improvements in HbA1c, with slightly lower mean weight loss, lower incidence of hypoglycemia, and better gastrointestinal tolerability compared with exenatide twice daily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with EX, the frequency of subcutaneous injection of LIXI is less, and the incidence of gastrointestinal adverse reactions and hypoglycemia is lower. Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“tric emptying, and are associated with beneficial effects on weight and appetite reduction (9).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“(27), exenatide 10 mg twice daily reduced HbA1c by 0.”
BackgroundResultBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Higher rates have been reported in studies with other background therapies (51% in combination with a sulfonylurea) (32,33).”
ResultSelf-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · cited 1×
“GLP-1 receptor agonists increasingly have become established as effective therapeutic options in type 2 diabetes management (6,7).”
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citation
Research works printed but not linked: 2
- Bolli, 2011, Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12–16 September 2011, Lisbon, Portugal, Diabetologia, 54, 1
- Riddle, 2013, 36, 2489
Cited by
Items 201–251 of 251
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Self-citationSchubert, A., Buchholt, A. T., Khoury, A. C. E., Kamal, A., & Taieb, V. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1310091 · Cited by 5
Gut hormones and Type 2 diabetes mellitus
Falinska, A. M., Tan, T., & Bloom, S. R. (2014) · Diabetes Management · doi:10.2217/dmt.14.47 · Cited by 4
Singh, R., & Daniell, H. (2026) · Plant Biotechnology Journal · doi:10.1111/pbi.70554 · Cited by 4
“Lixisenatide (Adlyxin, single proline substitution with modified C-terminus having six additional lysine amino acids compared to exenatide) is a structurally modified form of exenatide that requires only once daily injections (Rosenstock et al. 2013).”
Burcelin, R., & Bertolini, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70590-x · Cited by 5
Lixisenatide: clinical profile and available evidence
Dicembrini, I., Bigiarini, M., & Mannucci, E. (2013) · Diabetes Management · doi:10.2217/dmt.13.64 · Cited by 3
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedChan, W. B., Luk, A. O. Y., Chow, W. S., & Yeung, M. W. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12515 · Cited by 4
Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
Martínez, J. J. G. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.02.001 · Cited by 5
Shu, H., Gu, L., Men, L., & Lu, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0207-6 · Cited by 4
SKOLNIK, N., Dupree, R. S., & Johnson, E. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1359518 · Cited by 3
Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 3
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 2
“Though not all of the 14 head-to-head trials explicitly reported the rate of injection site reactions, data from the ones that did demonstrated exenatide QW to lead to the highest occurrence [up to 16% of the patients] [10–15,21] (Table 2).”
InfluentialBolli, G. B., Deeb, L. C., Garg, S. K., Leahy, J. L., Mazze, R. S., Owens, D. R., Riddle, M. C., Southerland, P., & Strock, E. S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0179 · Cited by 2
Fricke, U., & Schwabe, U. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_2 · Cited by 2
GLP ‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity
Linderoth, L., Kofoed, J., Kodra, J. T., Reedtz‐Runge, S., & Kruse, T. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch3 · Cited by 3
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 4
“…upper respiratory infections, diarrhea [30] Lixisenatide Stimulates insulin secretion 2-3% [31] Injection-site reactions, nausea, diarrhea [31] Cagrilintide Amylin analog; decreases appetite 6-10% [32] Nausea, diarrhea, injection-site reactions [32] Albiglutide Enhances satiety and delays…”
InfluentialOrtiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Vaciamiento gástrico y Diabetes mellitus tipo 2
Cadavid, C. A. Q., Regino, W. O., & Vega, R. F. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n2.46195 · Cited by 2
“El estudio GetGoal-X (56), orientado a demostrar no inferioridad de lixisenatide con respecto a exenatide, evidenció que tenían una eficacia similar en reducción de HbA1c como desenlace primario y con un perfil bastante similar en cuanto a disminución de peso, glucemia basal y efectos secundarios.”
BackgroundExtra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Araújo, L. M. D. M., Feguri, S., de Oliveira, T. L., Pedrosa, F. B., Guimarães, R. G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61007 · Cited by 2
Roca-Rodríguez, M. D. M., Tapia, M. J., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.07.003 · Cited by 1
Roca-Rodríguez, M. D. M., Tapia, M. J., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.07.004 · Cited by 1
Gysling, E. (2017) · pharma-kritik · doi:10.37667/pk.2017.1021 · Cited by 1
Freichel, M., & Mengel, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_14 · Cited by 1
Freichel, M., & Mengel, K. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_10 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
The Effect of Glucagon-like Peptide-1 (GLP-1) on Obesity
Huang, X., Liang, M., & Wei, B. (2019) · Critical Care Obstetrics and Gynecology · doi:10.21767/2471-9803.1000171 · Cited by 1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
Lyseng-Williamson, K. A., & Scott, L. J. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0059-3
Lixisenatide: A New Glucagon-Like Peptide-1 Agonist
Ho, C. W. (2013) · Journal of Developing Drugs · doi:10.4172/2329-6631.1000e134
Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos
Ampudia‐Blasco, F. J., & Perelló-Camacho, E. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.011 · Cited by 1
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
Managing problems with medications for type 2 diabetes
Morris, D. (2017) · Practice Nursing · doi:10.12968/pnur.2017.28.4.148
The Effect of Micro Element Levels in Drinking Water on Adolescent Body Composition
Çetin, İ., Nazik, A., Nalbantçılar, M. T., & Tosun, K. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.13471
Gallwitz, B. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0266-y
Martjanova, M. V., & Babenko, A. Y. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-7-50-55
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor
Chilton, A. (2015)
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Freichel, M., & Mengel, K. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_14
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Chacon, A. N., Su, W., Hou, T., Guo, Z., & Gong, M. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.02.601700
Hung, C.-M., Hsu, C., Zeng, B.-S., Suen, M., Chen, J.-J., Zeng, B., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T.-Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062619
Zarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Semaglutide and the Heart: Focus on Their Love–Hate Relationship
Khan, E., Fernandes, J., Gohel, V., Jain, R., Jayne, W., Peck, C., Shah, T. S., Shah, R. S., LaBarge, J., Ray, S. D., et al. (2026) · Hearts · doi:10.3390/hearts7030022
“Examples of prandial agonists include exenatide and lixisenatide [26].”
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
Metadata
- Authors
- Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E.
- Affiliations
- Medical City Dallas Hospital (US)
- Hôpital Sainte-Marguerite (FR)
- DRC Ltd, Balatonfüred, Hungary
- Investigación Clinica Aplicada, Buenos Aires, Argentina
- Sanofi (France) (FR)
- University of Rochester Medicine (US)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 2945-2951
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781502
- OpenAlex
- W2133648480
- Cited by
- 253
- References
- 29
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 10 · 2019: 12 · 2018: 20 · 2017: 41 · 2016: 33 · 2015: 24 · 2014: 34 · 2013: 16
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, type 2 diabetes, glycemic control, metformin, GLP-1 receptor agonists, HbA1c reduction, non-inferiority, weight loss, hypoglycemia, gastrointestinal adverse effects, nausea, adjunctive therapy, once-daily dosing, twice-daily dosing, fasting blood glucose
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
